The Procter & Gamble Company
PG remains a high-quality staples franchise, but FY27 EPS growth of just 0%-3% and a Q1 decline of 5% or more leave limited upside at $146.23.
PG is still one of the safer franchises in staples, but safety is already what the market is paying for. At $146.23, the stock sits only 12.6% below its 52-week high and essentially on top of the quant fair value of $147.3, even though FY26 growth was just 0.3% on revenue and 2.5% on EPS. That leaves little room for error in a year when management is openly preparing investors for a tough first half.
The near-term issue is simple: FY27 is shaping up as another grind. Management guided to 1%-3% organic sales growth, $6.89-$7.11 of core EPS, and said, "While we do not typically provide quarterly guidance, we estimate the cost dynamic will cause Q1 EPS to be down 5% or more versus prior year." That is a weak setup for a stock that still trades at 21.66x earnings. The $1B after-tax cost headwind from raw materials, energy, transportation, and Middle East-related premiums is concrete, not hypothetical, and most of it hits in 1H FY27. On top of that, restructuring is itself a 30-50 bps drag to organic sales this year.
The reason not to be outright bearish is that the core franchise is still functioning. Share trends improved through the back half, China returned to +4% organic growth, enterprise markets grew 4%, and Tide Evo is moving into national rollout. The earnings track record also matters: 7 beats in the last 8 quarters and FY26 delivered within management's initial guidance ranges. This is not a broken business. It is a mature business working through an inflation squeeze.
The case depends on three things. First, North America has to recover from -1% organic sales in Q4. Second, the company has to hold margins better than the ugly Q4 EBITDA margin of 8.6% suggests. Third, second-half relief on input costs has to materialize fast enough to protect the midpoint of $7.00 in FY27 EPS. If those happen, the stock can hold its ground and maybe revisit the upper-$160s. If they do not, there is not enough valuation support to protect returns. That balance keeps conviction at Medium and the rating at HOLD.
Input costs ease faster, Tide Evo supports mix and share, and second-half U.S. demand improves enough to push earnings toward $7.11 with a peer-like P/E.
Management offsets part of the $1B cost headwind, China stays positive, and PG delivers around the $7.00 center of FY27 guidance without a valuation rerate.
Input-cost inflation persists, North America stays weak, and FY27 EPS lands near the low end of $6.89, leading the market to value PG closer to a no-growth staples multiple.
Quant call (HOLD) diverges from analyst consensus (Strong Buy: 3 buy / 3 hold / 0 sell) — resolve explicitly.
The single greatest edge an investor can have is a long-term orientation.
FY27 earnings power looks capped at about $7.00 at the midpoint of guidance, which puts the stock around 20.9x forward EPS, only modestly below the 21.66x trailing multiple and not obviously mispriced for a business growing low single digits. The moat remains strong today because scale, distribution, advertising reach, and category leadership still protect shelf space and pricing, but over the next 3-5 years the edge likely shifts from pure brand spend toward data-driven demand sensing, supply-chain optimization, and product innovation speed. AI should help PG more as an efficiency tool than as a revenue unlock, especially in procurement, forecasting, and media targeting, but it is unlikely to change the company from a mature staples compounder into a faster grower. Regulation and category maturity are manageable, but TAM expansion remains limited, so the case still rests on steady share, productivity, and cash returns rather than acceleration.
- FY27 guidance is restrained at 1%-3% organic sales growth and 0%-3% core EPS growth, with management explicitly guiding Q1 EPS down 5% or more
- Valuation is mixed: P/E 21.66 sits below the 24.6 peer average, but P/S 4.07 is well above the 2.6 peer average
- The stock is near fair value: engine target $147.3, only 0.7% above the current $146.23, with price already just 0.9% below the 200-day average
- Management delivered FY26 within initial guidance ranges on organic sales, core EPS and cash returns despite volatile markets, and the earnings record shows 7 beats in the last 8 quarters
- Geographic pressure is improving: Greater China +4% organic sales in Q4 and FY26, with share growth returning after -15% organic sales in the 2025 Q1 period
- Global share exited FY26 flat with second-half improvement, while enterprise markets posted +4% organic sales in Q4, showing the portfolio is still holding demand in tougher markets
- Balance-sheet leverage remains manageable at Debt/EBITDA 1.65 and Debt/Equity 0.64, which supports continued dividends and buybacks even in a cost-heavy year
- Growth has slowed materially: FY26 revenue rose only 0.3% and EPS only 2.5%, versus the much stronger framework management laid out entering FY25
- Margins are under pressure: FY26 operating margin fell to 23.6% from 24.3%, and Q4 EBITDA margin was only 8.6%, down 1,960 bps year over year
- FY27 faces a concrete cost burden of $1B after tax from raw materials, energy, transportation and Middle East-related premiums, with most pressure in 1H FY27
- North America focus markets, still the core earnings engine, saw -1% organic sales in Q4, and management also flagged a 30-50 bps FY27 organic sales headwind from restructuring
| Metric | Value | Context |
|---|---|---|
| Current price | $146.23 | Reference price for the rating |
| Quant price target | $147.3 | Only 0.7% above current, Medium confidence |
| FY2026 revenue | $87.0B | 0.3% YoY growth, very muted |
| FY2026 EPS | $6.75 | 2.5% YoY growth |
| Operating margin | 23.6% | Down from 24.3% in the prior FY |
| Net margin | 18.4% | Still strong for staples, but not expanding |
| Valuation | P/E 21.66 | P/S 4.07 | P/B 6.52 | P/E below peer avg 24.6, P/S above peer avg 2.6 |
| Leverage | Debt/EBITDA 1.65 | Debt/Equity 0.64 | Manageable balance-sheet risk |
| Free cash flow | $4.9B | Supports dividends and modest buybacks |
| FY27 guidance | Organic sales 1%-3% | Core EPS $6.89-$7.11 | Implies 0%-3% EPS growth and a cautious year |
| Q1 FY27 outlook | EPS down 5% or more | Front-half cost pressure is the main issue |
| 52-week position | $137.82-$167.25 | Current price is -12.6% vs high and -0.9% below 200-day average |
The biggest risk is that the $1B after-tax input-cost headwind and weak North America demand push FY27 results toward the low end of $6.89-$7.11 core EPS, leaving the stock expensive on a no-growth earnings base.
The next catalyst is October 22, 2026 earnings, with the key watch item whether the guided Q1 EPS decline of 5% or more proves conservative and whether North America demand improves.
Ownership is crowded and stable, with the top three institutions holding 64.7% and insiders at just 0.1%, which fits PG's role as a defensive core holding rather than an idiosyncratic alpha story. Short interest is low at 1.02% of shares, or 24.2M shares and 2.7 days-to-cover, down 14%, so there is little squeeze setup and limited outright bearish conviction. Options positioning is mildly supportive, with a positive gamma regime and zero-gamma at $144.43, just 1.24% below spot, implying more pinning than breakout dynamics into earnings.
The dataset does not include segment revenue splits, but call commentary indicates broad portfolio resilience with global share flat exiting FY26 and Tide Evo as a notable launch focus.
Returned to growth at +4% organic sales in Q4 and FY26 after the much weaker -15% organic sales backdrop discussed in the 2025 Q1 call.
Q4 organic sales were down 1%, hurt by sell-in and sell-out mismatch, making this the most important near-term pressure point.
Stayed resilient at +4% organic sales in Q4, helping offset softness in more mature markets.
FY27 guide stayed cautious at 1%-3% organic sales growth despite improving consumption trends.
Execution has been credible, but not flawless. In the 2025 Q1 call, management held FY25 guidance at 3%-5% organic sales growth and $6.91-$7.05 of core EPS, while flagging China weakness at -15% organic sales and saying, "We will begin to annualize some of the steep market declines and SK-II headwinds late in December, though it will likely be a few more quarters until we return to growth in China." Since then, China did recover to +4% organic sales in Q4 and FY26, and Tide Evo remains on plan, with management now saying the national expansion is on track. The earnings record also supports credibility, with 7 beats in the last 8 quarters and FY26 landing within initial guidance ranges. The miss is that the business has clearly decelerated from the FY25 framework to FY26 actuals of only 0.3% revenue growth and 2.5% EPS growth, and FY27 guidance has reset lower to 1%-3% organic sales growth and 0%-3% core EPS growth, so management deserves credit for delivery discipline but not for restoring a stronger growth profile.
Taken together, our guidance range is for organic sales growth of 1% to 3% versus prior year, The low end of the range protects for additional softness in underlying market growth rates. The high end would require acceleration in underlying market growth rates. And market shares.
Our bottom line outlook is broadly consistent with top-line, with core EPS growth of 0% to 3% versus 2026 core EPS of $6.89 this guidance equates to a range of $6.89 to $7.11 per share, $7 at the center of the range.
While we do not typically provide quarterly guidance, we estimate the cost dynamic will cause Q1 EPS to be down 5% or more versus prior year.
For the fourth quarter, we saw improving global share trends versus prior period, but headline results were impacted by trade dynamics in the U.S. and the spike in input costs.
So we expect that momentum inthe U.S. to pick up during the semester behind some of these interventions.
PG's moat still comes from brand equity, category breadth, retailer relationships, procurement scale, and global distribution. Those advantages let it absorb shocks better than smaller peers and keep share broadly stable, shown by global share exiting FY26 flat with second-half improvement despite cost pressure. Durability looks good, but not unchallenged, because low category growth means the moat now has to defend margin and shelf position more than drive meaningful volume expansion.
Capital allocation remains disciplined but less aggressive than the old PG template. In the period provided, PG generated $4.9B of FCF, spent $1.0B on capex, returned $2.6B via dividends and $0.9B through buybacks, which is sensible given the $35.0B debt load and current cost headwinds. Management's FY27 capex plan of 4.5%-5.5% of sales suggests it is still funding innovation and supply chain capacity while preserving the dividend-first posture.
PG is a HOLD. The business remains durable and management is credible, but the combination of 0%-3% FY27 EPS growth, a $1B cost headwind, and only 0.7% upside to the $147.3 target does not justify fresh aggression at $146.23. This is a stock to own for stability, not for near-term upside. A move to BUY would require either a materially lower entry price or evidence that North America and margins are recovering faster than the current guide implies.
≣ Full research note tap to expand
Executive Summary
HOLD, Medium conviction. PG rates a HOLD at Medium conviction. The business is still durable, with steady category share, China recovery, and a strong dividend profile, but management's own outlook calls for only 1%-3% organic sales growth and $6.89-$7.11 of FY27 core EPS while absorbing a $1B after-tax cost headwind. At 21.66x earnings, below the 24.6x peer average but not cheap enough for a near-zero upside setup versus the $147.3 target, the stock looks more like a capital-preservation name than a return story.
Investment Thesis
PG is still one of the safer franchises in staples, but safety is already what the market is paying for. At $146.23, the stock sits only 12.6% below its 52-week high and essentially on top of the quant fair value of $147.3, even though FY26 growth was just 0.3% on revenue and 2.5% on EPS. That leaves little room for error in a year when management is openly preparing investors for a tough first half.
The near-term issue is simple: FY27 is shaping up as another grind. Management guided to 1%-3% organic sales growth, $6.89-$7.11 of core EPS, and said, "While we do not typically provide quarterly guidance, we estimate the cost dynamic will cause Q1 EPS to be down 5% or more versus prior year." That is a weak setup for a stock that still trades at 21.66x earnings. The $1B after-tax cost headwind from raw materials, energy, transportation, and Middle East-related premiums is concrete, not hypothetical, and most of it hits in 1H FY27. On top of that, restructuring is itself a 30-50 bps drag to organic sales this year.
The reason not to be outright bearish is that the core franchise is still functioning. Share trends improved through the back half, China returned to +4% organic growth, enterprise markets grew 4%, and Tide Evo is moving into national rollout. The earnings track record also matters: 7 beats in the last 8 quarters and FY26 delivered within management's initial guidance ranges. This is not a broken business. It is a mature business working through an inflation squeeze.
The case depends on three things. First, North America has to recover from -1% organic sales in Q4. Second, the company has to hold margins better than the ugly Q4 EBITDA margin of 8.6% suggests. Third, second-half relief on input costs has to materialize fast enough to protect the midpoint of $7.00 in FY27 EPS. If those happen, the stock can hold its ground and maybe revisit the upper-$160s. If they do not, there is not enough valuation support to protect returns. That balance keeps conviction at Medium and the rating at HOLD.
Key Metrics
| Metric | Value | Context | ||
|---|---|---|---|---|
| Current price | $146.23 | Reference price for the rating | ||
| Quant price target | $147.3 | Only 0.7% above current, Medium confidence | ||
| FY2026 revenue | $87.0B | 0.3% YoY growth, very muted | ||
| FY2026 EPS | $6.75 | 2.5% YoY growth | ||
| Operating margin | 23.6% | Down from 24.3% in the prior FY | ||
| Net margin | 18.4% | Still strong for staples, but not expanding | ||
| Valuation | P/E 21.66 | P/S 4.07 | P/B 6.52 | P/E below peer avg 24.6, P/S above peer avg 2.6 |
| Leverage | Debt/EBITDA 1.65 | Debt/Equity 0.64 | Manageable balance-sheet risk | |
| Free cash flow | $4.9B | Supports dividends and modest buybacks | ||
| FY27 guidance | Organic sales 1%-3% | Core EPS $6.89-$7.11 | Implies 0%-3% EPS growth and a cautious year | |
| Q1 FY27 outlook | EPS down 5% or more | Front-half cost pressure is the main issue | ||
| 52-week position | $137.82-$167.25 | Current price is -12.6% vs high and -0.9% below 200-day average |
Financial Strength
PG's balance sheet is solid enough for a defensive staples name, but it is not so strong that valuation can ignore weaker growth. Leverage at 1.65x Debt/EBITDA is manageable, and the franchise still converts enough cash to fund capex, dividends, and some buybacks. The concern is not solvency, it is cash efficiency and margin direction: FY26 operating margin fell to 23.6% and Q4 margin deterioration was sharp, so the balance sheet gives PG time, but not immunity, if cost inflation lasts longer than management expects.
Competitive Position
PG's moat still comes from brand equity, category breadth, retailer relationships, procurement scale, and global distribution. Those advantages let it absorb shocks better than smaller peers and keep share broadly stable, shown by global share exiting FY26 flat with second-half improvement despite cost pressure. Durability looks good, but not unchallenged, because low category growth means the moat now has to defend margin and shelf position more than drive meaningful volume expansion.
Management & Guidance
Guidance is deliberately conservative and likely realistic. Management is telling investors to expect 1%-3% organic sales growth, $6.89-$7.11 core EPS, and a Q1 EPS decline of 5% or more, which lines up with the disclosed $1B after-tax cost headwind and the fact that pressure is concentrated in the first half. Credibility is decent because PG has beaten expectations in 7 of the last 8 quarters and FY26 finished within initial guide rails, but the company is not signaling a hidden rebound. This is a defend-the-model year, not a step-change growth year.
Segment Analysis
- Product segments (Not provided): The dataset does not include segment revenue splits, but call commentary indicates broad portfolio resilience with global share flat exiting FY26 and Tide Evo as a notable launch focus.
- Greater China (Not provided): Returned to growth at +4% organic sales in Q4 and FY26 after the much weaker -15% organic sales backdrop discussed in the 2025 Q1 call.
- North America focus markets (Not provided): Q4 organic sales were down 1%, hurt by sell-in and sell-out mismatch, making this the most important near-term pressure point.
- Enterprise markets (Not provided): Stayed resilient at +4% organic sales in Q4, helping offset softness in more mature markets.
Capital Allocation
Capital allocation remains disciplined but less aggressive than the old PG template. In the period provided, PG generated $4.9B of FCF, spent $1.0B on capex, returned $2.6B via dividends and $0.9B through buybacks, which is sensible given the $35.0B debt load and current cost headwinds. Management's FY27 capex plan of 4.5%-5.5% of sales suggests it is still funding innovation and supply chain capacity while preserving the dividend-first posture.
Management Execution & Track Record
Execution has been credible, but not flawless. In the 2025 Q1 call, management held FY25 guidance at 3%-5% organic sales growth and $6.91-$7.05 of core EPS, while flagging China weakness at -15% organic sales and saying, "We will begin to annualize some of the steep market declines and SK-II headwinds late in December, though it will likely be a few more quarters until we return to growth in China." Since then, China did recover to +4% organic sales in Q4 and FY26, and Tide Evo remains on plan, with management now saying the national expansion is on track. The earnings record also supports credibility, with 7 beats in the last 8 quarters and FY26 landing within initial guidance ranges. The miss is that the business has clearly decelerated from the FY25 framework to FY26 actuals of only 0.3% revenue growth and 2.5% EPS growth, and FY27 guidance has reset lower to 1%-3% organic sales growth and 0%-3% core EPS growth, so management deserves credit for delivery discipline but not for restoring a stronger growth profile.
Positioning & Flows
Ownership is crowded and stable, with the top three institutions holding 64.7% and insiders at just 0.1%, which fits PG's role as a defensive core holding rather than an idiosyncratic alpha story. Short interest is low at 1.02% of shares, or 24.2M shares and 2.7 days-to-cover, down 14%, so there is little squeeze setup and limited outright bearish conviction. Options positioning is mildly supportive, with a positive gamma regime and zero-gamma at $144.43, just 1.24% below spot, implying more pinning than breakout dynamics into earnings.
Bull Case
- Management delivered FY26 within initial guidance ranges on organic sales, core EPS and cash returns despite volatile markets, and the earnings record shows 7 beats in the last 8 quarters
- Geographic pressure is improving: Greater China +4% organic sales in Q4 and FY26, with share growth returning after -15% organic sales in the 2025 Q1 period
- Global share exited FY26 flat with second-half improvement, while enterprise markets posted +4% organic sales in Q4, showing the portfolio is still holding demand in tougher markets
- Balance-sheet leverage remains manageable at Debt/EBITDA 1.65 and Debt/Equity 0.64, which supports continued dividends and buybacks even in a cost-heavy year
Bear Case
- Growth has slowed materially: FY26 revenue rose only 0.3% and EPS only 2.5%, versus the much stronger framework management laid out entering FY25
- Margins are under pressure: FY26 operating margin fell to 23.6% from 24.3%, and Q4 EBITDA margin was only 8.6%, down 1,960 bps year over year
- FY27 faces a concrete cost burden of $1B after tax from raw materials, energy, transportation and Middle East-related premiums, with most pressure in 1H FY27
- North America focus markets, still the core earnings engine, saw -1% organic sales in Q4, and management also flagged a 30-50 bps FY27 organic sales headwind from restructuring
Valuation & Price Target
Engine price target $147.3 (+0.7% vs current), Medium confidence.
- P/E Multiple: $167.38 (28% weight)
- P/S Multiple: $95.2 (20% weight)
- Quality-adjusted: $153.25 (20% weight)
- DCF: $188.95 (9% weight)
The rating stays aligned with the quant baseline HOLD, and the numbers support that restraint. The engine target is $147.3, only 0.7% above the current $146.23, while management's FY27 midpoint implies roughly $7.00 of core EPS and a forward multiple near 21x for a company guiding 0%-3% EPS growth and a Q1 decline of 5% or more. That is not cheap enough to justify a BUY, even with better-than-peer quality and a strong beat record. Sell-side consensus sits at Strong Buy from 3 buy / 3 hold / 0 sell, but that is low-signal context here and does not outweigh the company's own cautious outlook, margin pressure, and limited target upside.
Risk Assessment
Risk score 51/100 (Moderate). The biggest risk is that the $1B after-tax input-cost headwind and weak North America demand push FY27 results toward the low end of $6.89-$7.11 core EPS, leaving the stock expensive on a no-growth earnings base.
The Bottom Line
PG is a HOLD. The business remains durable and management is credible, but the combination of 0%-3% FY27 EPS growth, a $1B cost headwind, and only 0.7% upside to the $147.3 target does not justify fresh aggression at $146.23. This is a stock to own for stability, not for near-term upside. A move to BUY would require either a materially lower entry price or evidence that North America and margins are recovering faster than the current guide implies.
Go deeper in the app
Live charts, options analytics, the full earnings-call breakdown, price alerts, and every other stock — updated in real time.
Get Tickr